“The nation’s leading veterinary organization is joining the effort to reschedule cannabis under federal law. At its recent conference in Indianapolis, the American Veterinary Medical Association (AVMA) approved a resolution recommending that its board of directors ‘investigate working with other research organizations and medical stakeholders to reclassify cannabis from Schedule 1 to Schedule 2 to facilitate research opportunities for veterinary and human medical uses.’
Founded in 1863, the AVMA is a nonprofit organization that has more than 89,000 members. As of now, the AVMA does not have a policy on marijuana research.
…Veterinarians at Colorado State University are currently conducting two clinical trials investigating the safety and efficacy of CBD in dogs with epilepsy and osteoarthritis. Research so far suggests that CBD has low toxicity and high tolerability in both animals and humans.”
This makes intuitive sense in that all mammals – not just humans – have endocannabinoid systems, and so should respond somewhat similarly to cannabis’ phytocannabinoids.
Vets warn, though, that large doses of the psychoactive cannabinoid THC, have been found to be toxic for dogs, so medicines need to be formulated to be pet-specific.
Meanwhile, there are many and growing anecdotal reports of success in using cannabis to treat symptoms in pets, and there are whole lines of medical cannabis products formulated for dogs and cats available in legal states.
Our pets are often among our closest companions and certainly deserve their caretakers being able to choose what they believe is best medical care available – and it is available at reasonable prices compared to many veterinary prescription drug products.
PS: More in the article – including a unique Utah angle on the story (about edible hemp products and animals).
#MMJ #Pets #Veterinarians #UTpol #TRUCE